iToBoS at the SCE Open Innovation Challenge 2024

12/11/2024.

iToBoS project participated in the SCE Open Innovation Challenge 2024, an event aimed at meeting innovative solutions and technological challenges within the framework of the Smart City Expo World Congress.

The Ugly Duckling Sign in Total Body Photography

11/11/2024.

In dermatology, the term “ugly duckling” takes on a significant and practical meaning.

Deep Tech Summit 2024

5/11/2024.

The Barcelona Deep Tech Summit 2024 focused on finding solutions to global challenges through conferences, roundtables, workshops and more.

Stereophotogrammetry

4/11/2024.

Stereophotogrammetry follows the principle of human visual perception to interpret the 3D information of an object from a digital camera.

Socio-cultural and ethical guidelines for future implementation of AI in the medical context: an innovative report for iToBoS project

31/10/2024.

This report is to provide guidelines on socio-cultural and ethical considerations for future development and exploitation of the iToBoS technologies.

3D Reconstruction Capabilities of the Total Body Scanner

28/10/2024.

The total body scanner developed in the iToBoS project mounts four collaborative robots (cobots) that move independently in order to gather the skin lesions on a patient’s body.

Perspectives for Generative Artificial Intelligence in Melanoma Patient Education

24/10/2024.

Generative artificial intelligence is revolutionizing our world at an unprecedented pace.

Image acquisition and transmission to the main computer

21/10/2024.

The images acquired by the HDIM Vision System should be transmitted to the main computer.

iToBoS presented in the World Congress of Dermoscopy

19/10/2024.

Dr. J. Malvehy was a speaker at the World Congress of Dermoscopy, held in Buenos Aires from October 16 to 19, 2024, at the Palacio de Congresos.

Indoor Tanning and the Risk of Melanoma

15/10/2024.

Cutaneous melanoma is currently the sixth most common type of cancer in Europe, with more than 150,000 new cases diagnosed in 2024 and its incidence continues to increase. The greatest increase in risk is observed in people under 40 years of age.